AMENDMENTS TO THE CLAIMS

Claims:

1.(Amended) A compound of formula I,



I

wherein

NRR_1 is attached at the 5- or 6-position of the furopyridine ring;

R is hydrogen, C_1-C_4 alkyl, or COR_2;

R_1 is $(CH_2)_nAr$, $CH_2CH=CHAr$, or $CH_2C\equiv CAr$;

n is 0 to 3;

A is N ~~or NO~~;

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or:

an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; any of which may optionally be substituted with one to two substitutents independently selected from: halogen, trifluoromethyl, or C_1-C_4 alkyl;

R_2 is hydrogen, C_1-C_4 alkyl; C_1-C_4 alkoxy; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH, OC_1–C_4 alkyl, CO_2R_5, –CN, $–NO_2$, $–NR_3R_4$, or $–CF_3$;

R_3, R_4 and R_5 are independently hydrogen; C_1-C_4 alkyl; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH, OC_1–C_4 alkyl,–CN; $–NO_2$, or $–CF_3$;

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

2-3. (Cancelled)

4. (Amended) A compound according to claim 1 ~~or 2~~, wherein R_1 is $CH_2CH=CHAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

5. (Amended) A compound according to claim 1 ~~or 2~~, wherein R_1 is $CH_2C\equiv CAr$; or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

6. (Cancelled)

7. (Amended) A compound according to any one of claims 1, 4 or ~~to~~ 5, wherein Ar is selected from the group: 1-, or 2-naphthyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl; 2-, 4-, 5-, 6-, or 7-benzoxazolyl; and 3-, 4-, 5-, 6-, or 7-benzisoxazolyl;
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

8. (Amended) A compound according to any one of claims 1, 4 or 5 ~~to 6~~, wherein R_3, R_4 and R_5 are independently hydrogen, or C_1-C_4 alkyl;
or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

9-10.(Cancelled)

11. (Amended) A compound according to any one of claims 1, 4, 5, 7 or ~~to~~ 8, wherein Ar is an heteroaromatic ring.

12. (Amended) A compound according to any one of claims 1, 4, 5, 7 or ~~to~~ 8 wherein n is 1; R is hydrogen and Ar is an heteroaromatic ring.

13. (Cancelled)

14. (Amended) A compound according to claim 1, said compound being: R-(–)-5'-(3-Pyridylmethyl) aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(–)-5'-(4-Pyridylmethyl) aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

15-43. (Cancelled)